Hope on the Horizon for Alzheimer's Patients and Caregivers
Published : 2010-11-21
Author : USF Health's Byrd Alzheimer's Institute
Synopsis* : New medicines in the pipeline for Alzheimers disease and other dementias.
Main DigestUSF Health Byrd Alzheimer's Institute researchers to discuss latest advances, including new medications in the pipeline.
America's biopharmaceutical research companies highlighted the 98 new medicines in the pipeline for Alzheimer's disease and other dementias, either in clinical trials or awaiting FDA review. Researchers, patients, caregivers, advocacy groups and students gathered at the University of South Florida Health Byrd Alzheimer's Institute to discuss the newest advances in Alzheimer's research and to take a look into the future of this debilitating disease. Currently, there are only five medicines approved for Alzheimer's. While these medicines temporarily reduce the symptoms for some patients, biopharmaceutical companies are working to develop new medicines to prevent, delay or cure Alzheimer's.
"The American biomedical enterprise is making progress in the treatment of Alzheimer's disease," said Dr. David Morgan, CEO of the Institute. "The richness of the public-private partnerships between universities, research institutes, biotechnology companies and major biopharmaceutical companies is the envy of the world."
Research facilities, like the USF Health Byrd Alzheimer's Institute are making breakthroughs with this devastating disease. These advances have expedited the understanding of the causes of Alzheimer's. New imaging technologies, such as positron emission tomography (PET) scans, provide scientists a glimpse into the brain, overcoming the prior inability to access brain tissue. PET scans and other biomarkers are revealing the earliest signs of Alzheimer's even before symptoms appear.
The Honorable Johnnie Byrd, Jr., founder and board member of the Institute highlights the importance of the research conducted at the Institute and the economic impact of the disease.
"As of 2010, the estimated total cost of caring for Alzheimer's patients is $172 billion, including Medicare, private insurance, out-of-pocket costs and uncompensated care. Families drain their life savings and lose their homes paying for care," stated Mr. Byrd.
Today, more than five million Americans are living with dementia, and one in 40 Floridians has dementia. Alzheimer's disease, the most common form of dementia, has become the seventh leading cause of death in America, and is the only cause of death that is moving up in the rankings. Alzheimer's is a disease of aging, with typical onset in the late 70s and 80s. The number of Americans living with Alzheimer's is expected to increase as the baby boomers age, and people live longer due to advances in treating infections, heart disease and cancer. It is estimated that 10 million baby boomers will die of this disease without a treatment that slows or prevents Alzheimer's.
For more information on USF Health's Byrd Alzheimer's Institute, visit health.usf.edu/nocms/byrd
You're reading Disabled World. Be sure to check out our homepage for further informative disability news, reviews, disability sports events, exclusive stories and how-tos. You can also find us on Twitter, Facebook, and LinkedIn.
Related Alzheimer's Disease Documents
- 1 - OCTA Eye Scan May Detect Sign of Early Alzheimer's Disease : Results from two studies show that a new, non-invasive imaging device can see signs of Alzheimer's disease in a matter of seconds.
- 2 - Music Activates Regions of the Brain Spared By Alzheimer's Disease : Researchers at the University of Utah Health looking to the salience network of the brain to develop music based treatments to help alleviate anxiety in patients with dementia.
- 3 - Importance of Family History for Onset of Alzheimer's Disease : Study reveals the closer a person gets to the age at which their parent exhibited the first signs of Alzheimer's disease, the more likely they are to have amyloid plaques, the cause of the cognitive decline.
- 4 - Probiotics Improve Memory in People with Alzheimers Disease : Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: a randomized, double-blind, and controlled trial.
- 5 - Major Study Into Early Signs of Alzheimer's Disease : Deep and Frequent Phenotyping study hopes to dramatically improve success rate of clinical trials for treatments in Alzheimer's disease.
*Disclaimer: Disabled World provides general information only. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information. Please report outdated or inaccurate information to us.
Journal: Disabled World. Language: English (U.S.). Author: USF Health's Byrd Alzheimer's Institute. Electronic Publication Date: 2010-11-21. Title: Hope on the Horizon for Alzheimer's Patients and Caregivers, Source: <a href=https://www.disabled-world.com/health/aging/alzheimers/future-medicine.php>Hope on the Horizon for Alzheimer's Patients and Caregivers</a>. Retrieved 2021-05-07, from https://www.disabled-world.com/health/aging/alzheimers/future-medicine.php - Reference: DW#187-6244.